RetaMaps

Penn Medicine Endocrinology — Hamdee Attallah, MD

Hospital of the University of Pennsylvania — West Pavilion · 3400 Civic Center Boulevard, West Pavilion, 4th Floor · Philadelphia, PA 19104

2.6· 11 Google reviews

Listing updated October 2, 2026

Retatrutide outlook for this practice

No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.

About this practice

Penn Medicine Endocrinology, Diabetes and Metabolism is an academic hospital program treating diabetes, thyroid, pituitary, metabolic, obesity, and related hormone disorders, with team-based care, clinical trials, and insurance-based scheduling. Hamdee Attallah, MD, is Professor of Clinical Medicine and Section Chief of Endocrinology at the Philadelphia VA; he sees adults 18+ at the Hospital of the University of Pennsylvania West Pavilion (3400 Civic Center Boulevard). Official pages accept insurance and do not name GLP-1 brands.

Services & access

Advertises semaglutide todayNot listed
Advertises tirzepatide todayNot listed
Telehealth visitsNot listed
Cash pay acceptedYes
Accepts insurance — per practice websiteYes
Accepting new patients — per practice websiteYes

"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.

Review activity

★ 2.6
Google rating · 11 reviews
2
reviews in the past year (avg ★ 1.0)
1
reviews mention GLP-1 medications

Counts computed by RetaMaps from public Google reviews; most recent review 2026-02-25. Read the reviews themselves on the practice's Google listing.

Clinicians

  • Hamdee Attallah, MD

Nearby providers in Philadelphia

Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026

Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.

Development
Phase 3 complete
FDA status
Submission planned — Q1 2027 (Lilly guidance)
Availability
Not commercially available
Access routes
Clinical trials, or Lilly's expanded access program (physician must apply)

Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)

Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs